WO2008147245A3 - Controlled release proxodolol pharmaceutical composition - Google Patents

Controlled release proxodolol pharmaceutical composition Download PDF

Info

Publication number
WO2008147245A3
WO2008147245A3 PCT/RU2007/000619 RU2007000619W WO2008147245A3 WO 2008147245 A3 WO2008147245 A3 WO 2008147245A3 RU 2007000619 W RU2007000619 W RU 2007000619W WO 2008147245 A3 WO2008147245 A3 WO 2008147245A3
Authority
WO
WIPO (PCT)
Prior art keywords
proxodolol
controlled release
pharmaceutically acceptable
active ingredient
pharmaceutical composition
Prior art date
Application number
PCT/RU2007/000619
Other languages
French (fr)
Russian (ru)
Other versions
WO2008147245A2 (en
Inventor
Sergei Danilovich Juzhakov
Robert Georgievich Glushkov
Viktor Vladimirovich Chistyakov
Natalya Vyacheslavovna Aristovskaya
Original Assignee
Otkrytoe Aktsionernoe Obschest
Sergei Danilovich Juzhakov
Robert Georgievich Glushkov
Chistyakov Viktor Vladimirovic
Aristovskaya Natalya Vyachesla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otkrytoe Aktsionernoe Obschest, Sergei Danilovich Juzhakov, Robert Georgievich Glushkov, Chistyakov Viktor Vladimirovic, Aristovskaya Natalya Vyachesla filed Critical Otkrytoe Aktsionernoe Obschest
Publication of WO2008147245A2 publication Critical patent/WO2008147245A2/en
Publication of WO2008147245A3 publication Critical patent/WO2008147245A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to medicine, in particular to pharmaceutic. A novel preparation exhibiting stable kinetic characteristics relating to delivery of an active substance is disclosed. The controlled release proxodolol pharmaceutical forms can be effectively and easily produced using a mixture of one or more expanding or gel-forming components, an active ingredient and a pharmaceutically acceptable filler. In the preferred embodiment, a preparation in the form of tablets containing proxodolol in a quantity of 120 mg, hypromellose and pharmaceutically acceptable fillers, for example microcristalline cellulose, calcium stearate and aerosil, is used. The novel pharmaceutical forms with a suitable proxodolol release make it possible to reduce the number of every day medications, whilst the concentration of the active ingredient remains constant within a therapeutic dose.
PCT/RU2007/000619 2007-06-01 2007-11-13 Controlled release proxodolol pharmaceutical composition WO2008147245A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2007120431/15A RU2356532C2 (en) 2007-06-01 2007-06-01 Controlled-release pharmaceutical proxodolol composition
RU2007120431 2007-06-01

Publications (2)

Publication Number Publication Date
WO2008147245A2 WO2008147245A2 (en) 2008-12-04
WO2008147245A3 true WO2008147245A3 (en) 2009-06-04

Family

ID=40075688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2007/000619 WO2008147245A2 (en) 2007-06-01 2007-11-13 Controlled release proxodolol pharmaceutical composition

Country Status (2)

Country Link
RU (1) RU2356532C2 (en)
WO (1) WO2008147245A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103477224B (en) * 2011-03-04 2015-12-23 贝克顿·迪金森公司 Blood collection device containing lysophosphatide enzyme inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014070A1 (en) * 1994-11-02 1996-05-17 Janssen Pharmaceutica N.V. Cisapride extended release oral compositions
WO2000021525A2 (en) * 1998-10-14 2000-04-20 Novartis Ag Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014070A1 (en) * 1994-11-02 1996-05-17 Janssen Pharmaceutica N.V. Cisapride extended release oral compositions
WO2000021525A2 (en) * 1998-10-14 2000-04-20 Novartis Ag Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent

Also Published As

Publication number Publication date
RU2007120431A (en) 2008-12-10
WO2008147245A2 (en) 2008-12-04
RU2356532C2 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
SI2529622T1 (en) Inhibitors of bruton's tyrosine kinase
JP2008543767A5 (en)
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
FI2508188T3 (en) Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
EA200801926A1 (en) TABLETS OF PARACETAMOL WITH FAST DELIVERY
UA116334C2 (en) SOLID FORMS OF BENDAMUSTINE DOSAGE
RU2333745C2 (en) Compositions with controlled liberation
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
BRPI0513598A (en) enteric release coated tablet dosage forms
WO2005055921A3 (en) Compositions for treatment of ear disorders and methods of use thereof
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
DE602005008128D1 (en) Cytisine-containing drug
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
IL179177A (en) Pharmaceutical composition comprising acyclovir and a delivery agent, a dosage unit, use of acyclovir in the preparation of the pharmaceutical composition, use of the pharmaceutical composition in the preparation of a medicament and a method of preparing the pharmaceutical composition
MX2008001532A (en) Pharmaceutical composition containing indometacin and/or acemetacin.
JP2016104812A (en) Solid preparation containing loxoprofen sodium and tranexamic acid
WO2008079343A3 (en) Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients
WO2003045305A3 (en) Acetaminophen compositions
WO2008147245A3 (en) Controlled release proxodolol pharmaceutical composition
JP2009526833A5 (en)
JP4138209B2 (en) Pravastatin-containing composition
CA2653017A1 (en) Robust sustained release formulations of oxymorphone and methods of use thereof
WO2011108882A3 (en) Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient
Shetty et al. Design and evaluation of sustained release matrix tablets of etodolac

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07861043

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07861043

Country of ref document: EP

Kind code of ref document: A2